Philippe Martin

Chief Research and Development Officer · Viatris

Pharmaceuticals

Philippe Martin is chief research and development officer of Viatris. He joined in September 2023 after R&D leadership at BioAtla and a decade of expanding development responsibilities at Celgene.

Last reviewed: Oct 21, 2026

Philippe Martin

Chief Research and Development Officer
Viatris

Last Reviewed: October 21, 2026

Executive Summary

Philippe Martin is chief research and development officer of Viatris. He joined in September 2023 after R&D leadership at BioAtla and a decade of expanding development responsibilities at Celgene.

Career Highlights

  • Joined Viatris in September 2023.
  • Previously led R&D at BioAtla.
  • At Celgene, advanced from project leadership to corporate vice president.

Professional Journey

Martin’s pharmaceutical development career included assignments at Schering-Plough, Aventis and Solvay before his nearly decade-long tenure at Celgene. There, he advanced from executive director of project leadership to corporate vice president. His responsibilities encompassed early- and late-stage development across inflammation and immunology, neurology, oncology and other therapeutic areas.

His Celgene work included development and commercialization of Otezla and Zeposia and oversight of large Phase 3 studies. He later led R&D at BioAtla, a biotechnology company focused on cancer therapies.

He joined Viatris in September 2023 and now leads its research and development function. His background spans small molecules, biologics and cell therapies, combining scientific development with business training. His company biography establishes graduate study in organic chemistry and an MBA, without claiming a medical degree or doctorate.

Education

  • Master’s degree in Organic Chemistry — Pierre and Marie Curie University
  • Master of Business Administration — emlyon business school